425: TuHURA Biosciences to Acquire Kineta, Bolstering Pipeline with Novel Checkpoint Inhibitor

TuHURA Biosciences has entered into a definitive agreement to acquire Kineta, adding a Phase 2 novel checkpoint inhibitor to its pipeline.

Summary

• TuHURA Biosciences has agreed to acquire Kineta, a clinical-stage biotech company, in a merger transaction.
• The acquisition includes Kinetas novel KVA12123 antibody, a VISTA-inhibiting immunotherapy.
• The merger consideration consists of a combination of cash and TuHURA common stock.
• The base cash amount is $9,005,000, adjusted for Kinetas working capital deficit and any working capital loans from TuHURA.
• Up to approximately 3,476,568 shares of TuHURA common stock will be issued, with a portion held back for potential liabilities.
• Kineta stockholders may also receive payments from potential pre-closing asset sales.
• TuHURA will fund KVA12123 clinical trial expenses up to $900,000, with potential for additional working capital loans to Kineta.
• The transaction is expected to close in the first quarter of 2025, pending approvals and other conditions.

Sentiment

Score: 7

Explanation: The document is generally positive, highlighting the strategic benefits of the acquisition and the potential of KVA12123. However, it also acknowledges the risks and uncertainties associated with the transaction, which tempers the overall sentiment.

Positives

• The acquisition adds a Phase 2 novel checkpoint inhibitor, KVA12123, to TuHURAs pipeline.
• KVA12123 has shown strong monotherapy tumor growth inhibition in preclinical models without evidence of CRS in clinical trial participants.
• The acquisition is expected to create synergies with TuHURAs existing technologies.
• The transaction is expected to maximize value for Kinetas shareholders.
• TuHURA will fund KVA12123 clinical trial expenses up to $900,000.

Negatives

• The cash component of the merger consideration is subject to adjustments based on Kinetas working capital deficit and loans.
• A portion of the TuHURA stock consideration will be held back for potential liabilities.
• The transaction is subject to various closing conditions, including stockholder approvals and financing.
• The transaction is subject to various closing conditions, including Kinetas working capital deficit not exceeding $12,000,000 at the time of closing.

Risks

• The completion of the Proposed Transaction is subject to various conditions, including stockholder approvals and financing.
• There are uncertainties related to Kinetas cash level and ability to continue as a going concern.
• The price of TuHURA common stock and Kineta common stock could change before the completion of the Proposed Transaction.
• There are risks relating to the amount of Kinetas estimated net working capital at the closing of the Proposed Transaction.
• There are uncertainties as to access to available financing, including the required financing of TuHURA, to complete the Proposed Transaction.
• The Proposed Transaction could disrupt current plans and operations of Kineta or TuHURA.
• There is a risk that the Proposed Transaction does not qualify as a reorganization under the Internal Revenue Code.
• There is a risk of no amounts being payable under the Disposed Asset Payment Right.

Future Outlook

The Proposed Transaction is expected to close in the first quarter of 2025, pending approvals and other conditions. TuHURA plans to advance KVA12123 through clinical development, potentially combining it with its existing technologies.

Management Comments

• We believe the real potential for this class of checkpoint inhibitors resides in the treatment of blood related cancers.
• We believe KVA12123 has multiple synergies with both of TuHURAs IFx and Delta receptor antibody-drug conjugate (ADC) and peptide drug conjugate (PDC) technologies and that a TuHURA acquisition will provide the necessary resources to advance KVA12123 through its clinical development, maximizing value for Kinetas shareholders.

Industry Context

The acquisition reflects a trend in the biotech industry where companies are consolidating to strengthen their pipelines and leverage synergies. The focus on VISTA as a target for cancer immunotherapy is also a growing area of interest, with KVA12123 representing a novel approach to address immune suppression in the tumor microenvironment.

Comparison to Industry Standards

• The acquisition of Kineta by TuHURA is similar to other strategic acquisitions in the biotech industry where companies seek to expand their pipelines and leverage complementary technologies.
• The focus on VISTA as a target is in line with the industry's interest in novel checkpoint inhibitors, with companies like Jounce Therapeutics and Immutep also exploring this pathway.
• The clinical development of KVA12123, including its combination with pembrolizumab, is comparable to other checkpoint inhibitor programs in the industry.
• The financial terms of the acquisition, including the combination of cash and stock, are typical for transactions of this nature in the biotech sector.

Stakeholder Impact

• Kineta stockholders will receive a combination of cash and TuHURA stock.
• TuHURA stockholders will have their ownership diluted but will gain access to a promising new asset.
• Employees of both companies may experience changes due to the merger.
• Patients may benefit from the development of new cancer therapies.

Next Steps

• Kineta stockholders will vote on the approval of the merger agreement.
• TuHURA stockholders will vote on the approval of an increase in the number of authorized shares of TuHURA common stock.
• TuHURA will file a registration statement on Form S-4 with the SEC.
• The companies will work to satisfy other closing conditions.
• TuHURA will continue to fund clinical trial expenses for KVA12123.
• Kineta will continue to pursue partnership opportunities for some of its other non-KVA12123-related products and technologies.

Key Dates

Keywords

merger, acquisition, immunotherapy, checkpoint inhibitor, VISTA, KVA12123, oncology, biotechnology, clinical trial, cancer